Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Horton's Disease: Proof of Concept Study. (HORTOCI)
The usual percentage of patients receiving 0.1 mg/Kg/d or less of prednisone after 6 months of treatment is approximately 40%. We believe that adding tocilizumab to the corticotherapy in this protocol could increase the percentage from 40 to 70%.
From an immunological point of view, we believe we will see not only a fall in the Th17 response (as with corticoids alone), but also a rise in Treg lymphocytes.
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
- Percentage of Treg [ Time Frame: baseline ] [ Designated as safety issue: No ]
|Study Start Date:||September 2013|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01910038
|CHU de Dijon||Not yet recruiting|
|Dijon, France, 21079|
|Contact: Maud CARPENTIER 03.80.29.35.10 firstname.lastname@example.org|
|Principal Investigator: Bernard BONNOTTE|